Commentary

Article

Video

Importance of DCTs Moving Forward

Perceived barriers of DCTs can be quickly overcome to ensure their viability in clinical research.

In this interview from DIA 2023, Janice Chang, CEO of TransCelerate BioPharma, discusses the unique opportuntities presented by decentralized clinical trials (DCTs).

Newsletter

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Subscribe Now!
Related Videos
Related Content
Navigating Complexity: Strategies to Accelerate Modern Clinical Trials
August 8th 2025

Navigating Complexity: Strategies to Accelerate Modern Clinical Trials

Cindy Henderson
ACT Brief Episode 1: Placebos, Politics, and the Ethics of Vaccine Trials
August 8th 2025

ACT Brief Episode 1: Placebos, Politics, and the Ethics of Vaccine Trials

Applied Clinical Trials Editorial Staff
© JHVEPhoto - © JHVEPhoto - stock.adobe.com
August 8th 2025

FDA Crackdown on Trial Design: What July’s CRLs to Replimune and Capricor Mean for Sponsors

Andy Studna, Senior Editor
Unifying Industry to Better Understand GCP Guidance
August 8th 2025

Unifying Industry to Better Understand GCP Guidance

Andy Studna, Senior Editor
FDA Issues Complete Response Letter to Replimune for RP1 Combination Therapy in Advanced Melanoma
August 8th 2025

FDA Issues Complete Response Letter to Replimune for RP1 Combination Therapy in Advanced Melanoma

Don Tracy, Associate Editor
ODAC Votes Against Risk-Benefit Profile of GSK’s Blenrep Combinations in Relapsed/Refractory Multiple Myeloma
August 8th 2025

ODAC Votes Against Risk-Benefit Profile of GSK’s Blenrep Combinations in Relapsed/Refractory Multiple Myeloma

Don Tracy, Associate Editor
© 2025 MJH Life Sciences

All rights reserved.